# Breast Cancer FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/breast-cancer

> 18 upcoming FDA catalysts in breast Cancer: IBRANCE® (palbociclib, PFE) on Dec 2026 to Mar 2027 (topline data readout); IBRANCE® (palbociclib, PFE) on December 2026 (primary completion); Piqray (alpelisib, NVS) on Jan to Apr 2027 (topline data readout); Piqray (alpelisib, NVS) on January 2027 (primary completion); and 14 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| July 10, 2025 | [PF-07220060 primary completion](https://sec-api.dev/pdufa/pf-07220060) | PFE | Breast Cancer | completed | "NCT06465368 (A Study to Learn About the Study Medicine PF-07220060 Together With Letrozole Compared to Letrozole Alone in Women Post Menopause): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-10 (ACTUAL); Lead Sponsor Pfizer; Results First Posted 2026-07-15." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06465368)) |
| August 25, 2025 | [Dato-dxd primary completion](https://sec-api.dev/pdufa/dato-dxd) | AZN | Breast Cancer | completed | "NCT05374512 (A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-08-25 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05374512)) |
| June 2026 | [Revtorpyk (gedatolisib) primary completion](https://sec-api.dev/pdufa/gedatolisib) | CELC | Breast Cancer | delayed | "NCT05501886 (Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-06-30 (ESTIMATED); Lead Sponsor Celcuity Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05501886)) |
| July 15, 2026 | [PF-07220060 topline data readout](https://sec-api.dev/pdufa/pf-07220060) | PFE | Breast Cancer | completed | "NCT06465368 (A Study to Learn About the Study Medicine PF-07220060 Together With Letrozole Compared to Letrozole Alone in Women Post Menopause): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-10 (ACTUAL); Lead Sponsor Pfizer; Results First Posted 2026-07-15." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06465368?tab=results)) |
| Oct 2026 to Jan 2027 | [Truqap (capivasertib) topline data readout](https://sec-api.dev/pdufa/capivasertib) | AZN | Breast Cancer | scheduled | "NCT06635447 (Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-31 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06635447)) |
| October 2026 | [Truqap (capivasertib) primary completion](https://sec-api.dev/pdufa/capivasertib) | AZN | Breast Cancer | delayed | "NCT06635447 (Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-31 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06635447)) |
| Dec 2026 to Mar 2027 | [IBRANCE® (palbociclib) topline data readout](https://sec-api.dev/pdufa/palbociclib) | PFE | Breast Cancer | scheduled | "NCT05909397 (Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-30 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05909397)) |
| December 2026 | [IBRANCE® (palbociclib) primary completion](https://sec-api.dev/pdufa/palbociclib) | PFE | Breast Cancer | scheduled | "NCT05909397 (Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-30 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05909397)) |
| Jan to Apr 2027 | [Piqray (alpelisib) topline data readout](https://sec-api.dev/pdufa/alpelisib) | NVS | Breast Cancer | scheduled | "NCT05038735 (Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-28 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05038735)) |
| January 2027 | [Piqray (alpelisib) primary completion](https://sec-api.dev/pdufa/alpelisib) | NVS | Breast Cancer | scheduled | "NCT05038735 (Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-28 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05038735)) |
| Jul to Oct 2027 | [Imfinzi® (durvalumab) topline data readout](https://sec-api.dev/pdufa/durvalumab) | AZN | Breast Cancer | scheduled | "NCT06103864 (A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-07-28 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06103864)) |
| Jul to Oct 2027 | [PF-07248144 topline data readout](https://sec-api.dev/pdufa/pf-07248144) | PFE | Breast Cancer | scheduled | "NCT07062965 (A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-07-22 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07062965)) |
| July 2027 | [PF-07248144 primary completion](https://sec-api.dev/pdufa/pf-07248144) | PFE | Breast Cancer | scheduled | "NCT07062965 (A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-07-22 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07062965)) |
| July 2027 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | Breast Cancer | scheduled | "NCT06103864 (A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-07-28 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06103864)) |
| September 2027 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | Breast Cancer | scheduled | "NCT05629585 (A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09-01 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05629585)) |
| Sep to Dec 2027 | [Imfinzi® (durvalumab) topline data readout](https://sec-api.dev/pdufa/durvalumab) | AZN | Breast Cancer | scheduled | "NCT05629585 (A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09-01 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05629585)) |
| Feb to May 2028 | [Dato-dxd topline data readout](https://sec-api.dev/pdufa/dato-dxd) | AZN | Breast Cancer | scheduled | "NCT07205822 (A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-02 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07205822)) |
| February 2028 | [Dato-dxd primary completion](https://sec-api.dev/pdufa/dato-dxd) | AZN | Breast Cancer | scheduled | "NCT07205822 (A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-02 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07205822)) |
| Nov 2028 to Feb 2029 | [Imfinzi® (durvalumab) topline data readout](https://sec-api.dev/pdufa/durvalumab) | AZN | Breast Cancer | scheduled | "NCT06112379 (A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-11-20 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06112379)) |
| November 2028 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | Breast Cancer | scheduled | "NCT06112379 (A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-11-20 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06112379)) |
| Jan to Apr 2029 | [IBRANCE® (palbociclib) topline data readout](https://sec-api.dev/pdufa/palbociclib) | PFE | Breast Cancer | scheduled | "NCT06760637 (Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-01-02 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06760637)) |
| January 2029 | [IBRANCE® (palbociclib) primary completion](https://sec-api.dev/pdufa/palbociclib) | PFE | Breast Cancer | scheduled | "NCT06760637 (Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-01-02 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06760637)) |
| Mar to Jun 2029 | [Arm a: gedatolisib + palbociclib + fulvestrant topline data readout](https://sec-api.dev/pdufa/arm-a-gedatolisib-palbociclib-fulvestrant) | CELC | Breast Cancer | scheduled | "NCT06757634 (Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03-31 (ESTIMATED); Lead Sponsor Celcuity Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06757634)) |
| March 2029 | [Arm a: gedatolisib + palbociclib + fulvestrant primary completion](https://sec-api.dev/pdufa/arm-a-gedatolisib-palbociclib-fulvestrant) | CELC | Breast Cancer | scheduled | "NCT06757634 (Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03-31 (ESTIMATED); Lead Sponsor Celcuity Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06757634)) |

## Drugs

- [PF-07220060](https://sec-api.dev/pdufa/pf-07220060) (PFE)
- [Dato-dxd](https://sec-api.dev/pdufa/dato-dxd) (AZN)
- [Revtorpyk (gedatolisib)](https://sec-api.dev/pdufa/gedatolisib) (CELC)
- [Truqap (capivasertib)](https://sec-api.dev/pdufa/capivasertib) (AZN)
- [IBRANCE® (palbociclib)](https://sec-api.dev/pdufa/palbociclib) (PFE)
- [Piqray (alpelisib)](https://sec-api.dev/pdufa/alpelisib) (NVS)
- [Imfinzi® (durvalumab)](https://sec-api.dev/pdufa/durvalumab) (AZN)
- [PF-07248144](https://sec-api.dev/pdufa/pf-07248144) (PFE)
- [Arm a: gedatolisib + palbociclib + fulvestrant](https://sec-api.dev/pdufa/arm-a-gedatolisib-palbociclib-fulvestrant) (CELC)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/breast-cancer.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Breast Cancer FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/breast-cancer

```bibtex
@misc{secapidev_indications_breast_cancer_20261116,
  title        = {Breast Cancer FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/breast-cancer}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_breast_cancer_20261116","title":"Breast Cancer FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/breast-cancer","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
